These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Gross B; Staels B Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742 [TBL] [Abstract][Full Text] [Related]
6. PPAR dual agonists: are they opening Pandora's Box? Balakumar P; Rose M; Ganti SS; Krishan P; Singh M Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674 [TBL] [Abstract][Full Text] [Related]
7. Safety issues and prospects for future generations of PPAR modulators. Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730 [TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance. Patsouris D; Müller M; Kersten S Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425 [TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones as antidiabetic agents: A critical review. Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164 [TBL] [Abstract][Full Text] [Related]
10. [Peroxysome proliferator-activated receptors at pathogenesis and treatment of atherosclerosis (achievements, paradoxes and perspectives)]. Rasin MS Lik Sprava; 2014; (5-6):26-38. PubMed ID: 25906645 [TBL] [Abstract][Full Text] [Related]
11. A new insight into the treatment of diabetes by means of pan PPAR agonists. Chandra A; Kaur P; Sahu SK; Mittal A Chem Biol Drug Des; 2022 Dec; 100(6):947-967. PubMed ID: 34990085 [TBL] [Abstract][Full Text] [Related]
12. PPARs as therapeutic targets in cardiovascular disease. van Bilsen M; van Nieuwenhoven FA Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178 [TBL] [Abstract][Full Text] [Related]
13. PPARs and diabetes-associated atherosclerosis. Calkin AC; Jandeleit-Dahm KA; Sebekova E; Allen TJ; Mizrahi J; Cooper ME; Tikellis C Curr Pharm Des; 2007; 13(26):2736-41. PubMed ID: 17897018 [TBL] [Abstract][Full Text] [Related]
14. PPAR ligands: are they potential agents for cardiovascular disorders? Balakumar P; Rose M; Singh M Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434 [TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Jay MA; Ren J Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654 [TBL] [Abstract][Full Text] [Related]
16. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. Mansour M Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239 [TBL] [Abstract][Full Text] [Related]
17. Metabolic and additional vascular effects of thiazolidinediones. Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315 [TBL] [Abstract][Full Text] [Related]
18. PPAR agonists and the metabolic syndrome. Staels B Therapie; 2007; 62(4):319-26. PubMed ID: 17983557 [TBL] [Abstract][Full Text] [Related]
19. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. Heald M; Cawthorne MA Handb Exp Pharmacol; 2011; (203):35-51. PubMed ID: 21484566 [TBL] [Abstract][Full Text] [Related]
20. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Tenenbaum A; Motro M; Fisman EZ Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]